# ABSI catalysts: Absci Corp PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/absi/catalysts

> Absci Corp (ABSI) has 4 upcoming catalysts. The next is the ABS-201 trial start, mid-2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for ABSI?

Absci Corp (ABSI) has 4 upcoming catalysts. The next is the ABS-201 trial start, mid-2027. Press release filed with the SEC (EX-99): "With the safety, tolerability, and PK data being generated for ABS-201 in the company's ongoing HEADLINE trial, Absci anticipates initiation of the Phase 2 STORYLINE trial for endometriosis in mid-2027." [Calendar and source filings](https://sec-api.dev/companies/absi/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001672688-26-000150, https://www.sec.gov/Archives/edgar/data/1672688/000167268826000150/exhibit991-2026q310xqpr.htm (retrieved 2026-11-13). Last confirmed 2026-11-12. Cite: https://sec-api.dev/companies/absi/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Absci Corp |
| Ticker | ABSI (Nasdaq) |
| SEC CIK | 1672688 |
| SIC | 8731 |
| SEC filings | https://sec-api.dev/companies/absi |

## Cash runway

Cash $218.3M as of 2026-09-30; quarterly burn $29.5M; about 22.2 months of runway at that rate (XBRL company facts, accession 0001672688-26-000152).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb 2024 | [ABS-101 trial start](https://sec-api.dev/pdufa/abs-101) | ABSI |  | completed | "In February 2024, we initiated IND-enabling studies and expect to initiate Phase 1 clinical studies for ABS-101 in the first half of 2025, subject to clearance of an IND or equivalent regulatory filing." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1672688/000162828024046862/absi-20240930.htm)) |
| November 12, 2024 | [Absci Corp earnings report](https://sec-api.dev/companies/absi/catalysts) | ABSI |  | completed | "VANCOUVER, Wash. and NEW YORK, November 12, 2024 - Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000162828024046856/exhibit991-2024q310xqpr.htm)) |
| 1H 2025 | [ABS-101 trial start](https://sec-api.dev/pdufa/abs-101) | ABSI |  | scheduled | "Absci plans to initiate Phase 1 clinical studies for ABS-101 in the first half of 2025, with an interim data readout in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000162828025013455/exhibit991-2024q410xkpr.htm)) |
| March 18, 2025 | [Absci Corp earnings report](https://sec-api.dev/companies/absi/catalysts) | ABSI |  | completed | "VANCOUVER, Wash. and NEW YORK, March 18, 2025 - Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter and full year ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000162828025013455/exhibit991-2024q410xkpr.htm)) |
| May 2025 | [ABS-201 trial start](https://sec-api.dev/pdufa/abs-201) | ABSI |  | completed | "Table of Contents development as a potential treatment for Inflammatory Bowel Disease, we initiated the Phase 1 clinical trial in May 2025, and subject to successful completion of the Phase 1 clinical trial, we anticipate starting the Phase 1b/2a clinical trial by the first half of 2026; while for ABS-201, which is in development for the potential treatment of androgenetic alopecia, we anticipate filing an" ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1672688/000119312525165469/d908325d424b5.htm)) |
| May 13, 2025 | [Absci Corp earnings report](https://sec-api.dev/companies/absi/catalysts) | ABSI |  | completed | "VANCOUVER, Wash. and NEW YORK, May 13, 2025 - Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today reported financial and operating results for the quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000162828025025075/exhibit991-2025q110xqpr.htm)) |
| 2H 2025 | [ABS-101 interim data readout](https://sec-api.dev/pdufa/abs-101) | ABSI |  | scheduled | "Absci plans to initiate Phase 1 clinical studies for ABS-101 in the first half of 2025, with an interim data readout in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000162828025013455/exhibit991-2024q410xkpr.htm)) |
| August 12, 2025 | [Absci Corp earnings report](https://sec-api.dev/companies/absi/catalysts) | ABSI |  | completed | "VANCOUVER, Wash. and NEW YORK, August 12, 2025 - Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today reported financial and operating results for the quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000162828025039878/exhibit991-2025q210xqpr.htm)) |
| November 12, 2025 | [Absci Corp earnings report](https://sec-api.dev/companies/absi/catalysts) | ABSI |  | completed | "VANCOUVER, Wash. and NEW YORK, November 12, 2025 - Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today reported financial and operating results for the quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000167268825000082/exhibit991-2025q310xqpr.htm)) |
| Dec 2025 | [HEADLINE (headline) trial start](https://sec-api.dev/pdufa/headline) | ABSI |  | completed | "In December 2025, we initiated the HEADLINE™ Phase 1/2a clinical trial for ABS-201 (NCT07317544)." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000068/absi-20251231.htm)) |
| Dec 2025 | [ABS-201 trial start](https://sec-api.dev/pdufa/abs-201) | ABSI |  | completed | "Absci anticipates initiation of a Phase 1/2a clinical trial for ABS-201 in androgenetic alopecia in December 2025, with potential for an interim efficacy readout in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000167268825000082/exhibit991-2025q310xqpr.htm)) |
| early 2026 | [ABS-201 trial start](https://sec-api.dev/pdufa/abs-201) | ABSI |  | scheduled | "Absci anticipates initiation of a Phase 1/2a clinical trial for ABS-201 in early 2026, with potential for an interim efficacy readout in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000162828025039878/exhibit991-2025q210xqpr.htm)) |
| March 24, 2026 | [Absci Corp earnings report](https://sec-api.dev/companies/absi/catalysts) | ABSI |  | completed | "VANCOUVER, Wash. and NEW YORK, March 24, 2026 - Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter and full year ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000066/exhibit991-2025q410xkpr.htm)) |
| May 7, 2026 | [Absci Corp earnings report](https://sec-api.dev/companies/absi/catalysts) | ABSI |  | completed | "VANCOUVER, Wash. and NEW YORK, May 7, 2026 - Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended March 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000086/exhibit991-2026q110xqpr.htm)) |
| 2H 2026 | [ABS-201 interim data readout](https://sec-api.dev/pdufa/abs-201) | ABSI |  | scheduled | "Absci anticipates initiation of a Phase 1/2a clinical trial for ABS-201 in androgenetic alopecia in December 2025, with potential for an interim efficacy readout in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000167268825000082/exhibit991-2025q310xqpr.htm)) |
| 2H 2026 | [ABS-201 topline data readout](https://sec-api.dev/pdufa/abs-201) | ABSI |  | scheduled | "Such statements include, but are not limited to, statements regarding any or all of the following: development and clinical progress of Absci's pipeline programs, including ABS-201, the design, enrollment, conduct, and timelines of our ongoing Phase 1/2a HEADLINE™ trial of ABS-201 for androgenetic alopecia; the anticipated timing of an interim proof-of-concept data readout for ABS-201 in the second half of 2026; the potential advancement of ABS-201 into Phase 3 development; the anticipated initiation of a Phase 2 clinical trial of ABS-201 for endometriosis in" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000086/exhibit991-2026q110xqpr.htm)) |
| 2H 2026 | [Absci Corp interim data readout](https://sec-api.dev/companies/absi/catalysts) | ABSI |  | scheduled | "Androgenetic Alopecia (AGA): Accelerated Ph1/2a trial on track to initiate December 2025, with interim efficacy readout 2H2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000167268825000082/generalcorporatepresenta.htm)) |
| August 11, 2026 | [Absci Corp earnings report](https://sec-api.dev/companies/absi/catalysts) | ABSI |  | completed | "VANCOUVER, Wash. and NEW YORK, August 11, 2026 - Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000134/exhibit991-2026q210xqpr.htm)) |
| Q4 2026 | [Endometriosis trial start](https://sec-api.dev/pdufa/endometriosis) | ABSI |  | scheduled | "Expanding ABS-201 strategy to pursue endometriosis as additional indication; anticipate initiation of Phase 2 clinical trial in the fourth quarter of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000167268825000082/exhibit991-2025q310xqpr.htm)) |
| Q4 2026 | [ABS-201 trial start](https://sec-api.dev/pdufa/abs-201) | ABSI | endometriosis in late 2026 | scheduled | "Based on these and other considerations, we anticipate initiating a Phase 2 clinical trial evaluating ABS-201 in endometriosis in the fourth quarter of 2026, subject to review of available data, regulatory considerations and other factors, with potential proof-of-concept data in the second half of 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000136/absi-20260630.htm)) |
| November 12, 2026 | [Absci Corp earnings report](https://sec-api.dev/companies/absi/catalysts) | ABSI |  | completed | "VANCOUVER, Wash. and NEW YORK, November 12, 2026 - Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000150/exhibit991-2026q310xqpr.htm)) |
| mid-2027 | [ABS-201 trial start](https://sec-api.dev/pdufa/abs-201) | ABSI |  | scheduled | "With the safety, tolerability, and PK data being generated for ABS-201 in the company's ongoing HEADLINE trial, Absci anticipates initiation of the Phase 2 STORYLINE trial for endometriosis in mid-2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000150/exhibit991-2026q310xqpr.htm)) |
| 2H 2027 | [HMI-115 interim data readout](https://sec-api.dev/pdufa/hmi-115) | ABSI |  | scheduled | "Phase 2 PoC study could start as early as Q4 2026 with interim efficacy readout anticipated 2H 2027 STRONG BIOLOGICAL AND CLINICAL RATIONALE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000167268825000082/generalcorporatepresenta.htm)) |
| 2H 2027 | [Endometriosis topline data readout](https://sec-api.dev/pdufa/endometriosis) | ABSI |  | scheduled | "Absci anticipates initiation of a Phase 2 clinical trial for endometriosis in the fourth quarter of 2026, with a potential proof-of-concept readout in the second half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000167268825000082/exhibit991-2025q310xqpr.htm)) |
| 2H 2027 | [ABS-201 interim data readout](https://sec-api.dev/pdufa/abs-201) | ABSI | endometriosis in late 2026 | scheduled | "In addition, we anticipate initiating a Phase 2 clinical trial for ABS-201 in patients with endometriosis in late 2026, with a potential interim data readout in the second half of 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1672688/000167268825000084/absi-20250930.htm)) |

## Drugs

- [ABS-101](https://sec-api.dev/pdufa/abs-101): 
- [ABS-201](https://sec-api.dev/pdufa/abs-201): endometriosis in late 2026
- [Endometriosis](https://sec-api.dev/pdufa/endometriosis): 
- [HEADLINE (headline)](https://sec-api.dev/pdufa/headline): 
- [HMI-115](https://sec-api.dev/pdufa/hmi-115): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/absi/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ABSI catalysts: Absci Corp PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/absi/catalysts

```bibtex
@misc{secapidev_companies_absi_catalysts_20261116,
  title        = {ABSI catalysts: Absci Corp PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/absi/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_absi_catalysts_20261116","title":"ABSI catalysts: Absci Corp PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/absi/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
